FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers November 10, 2022 FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for... January 24, 2025 FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma February 12, 2021 Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... May 4, 2021 Load more HOT NEWS Dog Finds Woman’s Lost Wedding Ring At The Beach Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... A new target to slow down ageing and reduce blood cancer... Bean there done that: Can swapping to pulses be the new...
